Research programme: miRNA therapeutics - SiSaf/University of Leipzig
Latest Information Update: 31 Mar 2023
At a glance
- Originator University of Leipzig
- Class Antineoplastics; MicroRNAs
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Pancreatic cancer
Most Recent Events
- 02 Mar 2023 SiSaf announced its collaboration with the University of Leipzig to develop Bio-Courier targeted micro interfering RNAs (miRNA) for the treatment of Cancer
- 02 Mar 2023 Early research in Pancreatic cancer in Germany (Parenteral)
- 02 Mar 2023 Early research in Pancreatic cancer in United Kingdom (Parenteral)